These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 25865435)
21. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer. Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579 [TBL] [Abstract][Full Text] [Related]
22. A prospective comparative study of ultrasonography, contrast-enhanced MRI and 18F-FDG PET/CT for preoperative detection of axillary lymph node metastasis in breast cancer patients. Guney IB; Dalci K; Teke ZT; Kucuker KA Ann Ital Chir; 2020; 91():458-464. PubMed ID: 32213685 [TBL] [Abstract][Full Text] [Related]
23. Selective Sentinel Node Plus Additional Non-Sentinel Node Biopsy Based on an FDG-PET/CT Scan in Early Breast Cancer Patients: Single Institutional Experience. Kim J; Lee J; Chang E; Kim S; Suh K; Sul J; Song I; Kim Y; Lee C World J Surg; 2009 May; 33(5):943-9. PubMed ID: 19259728 [TBL] [Abstract][Full Text] [Related]
24. Whole-body Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514 [TBL] [Abstract][Full Text] [Related]
25. 18F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance in Lymphoma: Comparison With 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and With the Addition of Magnetic Resonance Diffusion-Weighted Imaging. Giraudo C; Raderer M; Karanikas G; Weber M; Kiesewetter B; Dolak W; Simonitsch-Klupp I; Mayerhoefer ME Invest Radiol; 2016 Mar; 51(3):163-9. PubMed ID: 26784400 [TBL] [Abstract][Full Text] [Related]
26. Positron Emission Tomography/Magnetic Resonance Imaging for Local Tumor Staging in Patients With Primary Breast Cancer: A Comparison With Positron Emission Tomography/Computed Tomography and Magnetic Resonance Imaging. Grueneisen J; Nagarajah J; Buchbender C; Hoffmann O; Schaarschmidt BM; Poeppel T; Forsting M; Quick HH; Umutlu L; Kinner S Invest Radiol; 2015 Aug; 50(8):505-13. PubMed ID: 26115367 [TBL] [Abstract][Full Text] [Related]
27. [ van Loevezijn AA; Stokkel MPM; Donswijk ML; van Werkhoven ED; van der Noordaa MEM; van Duijnhoven FH; Vrancken Peeters MTFD EJNMMI Res; 2021 Aug; 11(1):78. PubMed ID: 34417932 [TBL] [Abstract][Full Text] [Related]
28. Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Aukema TS; Straver ME; Peeters MJ; Russell NS; Gilhuijs KG; Vogel WV; Rutgers EJ; Olmos RA Eur J Cancer; 2010 Dec; 46(18):3205-10. PubMed ID: 20719497 [TBL] [Abstract][Full Text] [Related]
29. The role of ultrasonography and FDG-PET in axillary lymph node staging of breast cancer. Ahn JH; Son EJ; Kim JA; Youk JH; Kim EK; Kwak JY; Ryu YH; Jeong J Acta Radiol; 2010 Oct; 51(8):859-65. PubMed ID: 20670083 [TBL] [Abstract][Full Text] [Related]
30. Breast cancer staging in a single session: whole-body PET/CT mammography. Heusner TA; Kuemmel S; Umutlu L; Koeninger A; Freudenberg LS; Hauth EA; Kimmig KR; Forsting M; Bockisch A; Antoch G J Nucl Med; 2008 Aug; 49(8):1215-22. PubMed ID: 18632831 [TBL] [Abstract][Full Text] [Related]
31. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients. Choi WH; Yoo IR; O JH; Kim SH; Chung SK Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574 [TBL] [Abstract][Full Text] [Related]
32. Variations in (18)F-FDG uptake in breast cancer depending on PET/CT acquisition position. Lee JH; Jeon TJ; Ahn SG; Jeong J; Seok JW; Ryu YH Clin Radiol; 2016 Jan; 71(1):86-91. PubMed ID: 26646369 [TBL] [Abstract][Full Text] [Related]
33. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer. Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401 [TBL] [Abstract][Full Text] [Related]
34. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging. Groheux D; Giacchetti S; Delord M; Hindié E; Vercellino L; Cuvier C; Toubert ME; Merlet P; Hennequin C; Espié M J Nucl Med; 2013 Jan; 54(1):5-11. PubMed ID: 23213197 [TBL] [Abstract][Full Text] [Related]
35. [Performance of 18F-FDG PET/CT in the detection of primary breast cancer and staging of the regional lymph nodes]. Zhao TT; Li JG; Li YM Zhonghua Zhong Liu Za Zhi; 2007 Mar; 29(3):206-9. PubMed ID: 17649638 [TBL] [Abstract][Full Text] [Related]
36. FDG PET-CT for lymph node staging of bladder cancer: a prospective study of patients with extended pelvic lymphadenectomy. Jeong IG; Hong S; You D; Hong JH; Ahn H; Kim CS Ann Surg Oncol; 2015 Sep; 22(9):3150-6. PubMed ID: 25634779 [TBL] [Abstract][Full Text] [Related]
37. Added value of dedicated axillary hybrid 18F-FDG PET/MRI for improved axillary nodal staging in clinically node-positive breast cancer patients: a feasibility study. van Nijnatten TJA; Goorts B; Vöö S; de Boer M; Kooreman LFS; Heuts EM; Wildberger JE; Mottaghy FM; Lobbes MBI; Smidt ML Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):179-186. PubMed ID: 28905091 [TBL] [Abstract][Full Text] [Related]
38. Axillary lymph node characterization in breast cancer patients using magnetic resonance mammography: a prospective comparative study with FDG PET-CT and healthy women. Krammer J; Wasser K; Schnitzer A; Henzler T; Schoenberg SO; Kaiser CG Eur J Radiol; 2013 Dec; 82(12):2194-8. PubMed ID: 23993142 [TBL] [Abstract][Full Text] [Related]
39. Potential impact of 18F-FDG PET/CT on patients selection for neoadjuvant chemotherapy before radical cystectomy. Rouanne M; Girma A; Neuzillet Y; Vilain D; Radulescu C; Letang N; Yonneau L; Hervé JM; Botto H; Le Stanc E; Lebret T Eur J Surg Oncol; 2014 Dec; 40(12):1724-30. PubMed ID: 25242381 [TBL] [Abstract][Full Text] [Related]
40. Implication of ¹⁸F-Fluorodeoxyglucose Uptake of Affected Axillary Lymph Nodes in Cases with Breast Cancer. Fujii T; Yajima R; Tatsuki H; Oosone K; Kuwano H Anticancer Res; 2016 Jan; 36(1):393-7. PubMed ID: 26722071 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]